-
October 12, 2020
Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium
-
September 21, 2020
Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
-
September 10, 2020
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
-
August 5, 2020
Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
-
August 3, 2020
Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August
-
August 3, 2020
Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924
-
June 29, 2020
Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan
-
June 10, 2020
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
-
June 4, 2020
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock
-
June 3, 2020
Aileron Therapeutics Announces Proposed Public Offering of Common Stock